Description: On August 19th, the Food and Drug Administration approved lazertinib in combination with amivantamab for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. In this episode of Lung Cancer Considered, host Dr. Narjust Florez talks with Dr. Julia Rotow about this therapy and the MARIPOSA trial, which evaluated the use of lazertinib in combination with amivantamab..

Guest: Dr. Julia Rotow, Clinical Director of the thoracic oncology group at Dana-Faber Cancer Institute, Assistant Professor of Medicine at Harvard Medical School.